RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Brazil: Consultation Open on Criteria for Priority Review

Brazil: Consultation Open on Criteria for Priority Review

Posted 24 April 2012 | By Louise Zornoza

The Public Consultation - CP No. 26 - on proposed new criteria for establishing the priority review for registration of medicines opened on April 20 and comments may be submitted within 30 days.

The proposal would grant priority review according to a points system to products that reach at least 10 points.

The application for prioritization would have to be made electronically and ANVISA would have 75 days to decide on petitions for priority registration, 90 days for post-registration priority, and 45 days for prior consent for clinical research.

Read more:

ANVISA - Consulta Pública nº 26, de 11 de abril de 2012

More Breaking News from RegLink


© 2022 Regulatory Affairs Professionals Society.